Novo Nordisk to use Trialbee's services for e-recruitment of patients for clinical studies

Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in important efficiency gains for the pharmaceutical company.

Novo Nordisk will use Trialbee's services for e-recruitment of patients to planned studies in Sweden, Norway and Denmark. The studies are phase II and III requiring patients with type I and II diabetes.

"Trialbee's solution is highly attractive since it directly targets patients and enables them to engage in clinical studies. E-recruitment follows the trend of patients increasingly seeking disease information online. Trialbee's recruitment technology solves a large, well known and costly problem within the pharmaceutical industry," says Marianne Pilgaard, Head of Clinical Research, Novo Nordisk Scandinavia.

The partnership with Novo Nordisk is an important milestone in Trialbee's establishment on the arena for global pharmaceutical companies.

"Novo Nordisk is the market leader within its segment and has a longstanding and broad experience within research and development. Novo Nordisk has a solid pipeline within diabetes and haemophilia and several clinical trials are expected in the coming years. At Trialbee, we are delighted to cooperate with Novo Nordisk, a company in the forefront of communicating with and engaging patients in product development," says Tobias Folkesson, CEO, Trialbee.

SOURCE Trialbee

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spermidine regulates RIPK1 to combat diabetes and vascular damage